IFRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InflaRx NV (IFRX) is not a strong buy at the moment for a beginner, long-term investor. While there is positive sentiment from analysts and hedge fund activity, the lack of significant financial data, technical indicators showing no clear trend, and no strong proprietary trading signals suggest a cautious approach. The stock may be worth monitoring for future developments, but it does not currently present a compelling entry point.
The technical indicators are neutral. The MACD histogram is negative and contracting (-0.0431), RSI is neutral at 51.512, and moving averages are converging. The stock is trading near its pivot point (1.742) with resistance at 1.915 and support at 1.57.
Hedge funds are significantly increasing their positions in the stock, with a 425.33% increase in buying activity over the last quarter.
Analysts have upgraded the stock, with price targets ranging from $5 to $9, citing promising clinical developments and financing that supports further research.
No recent news or significant insider trading activity.
Technical indicators do not show a strong upward trend.
Lack of financial performance data to evaluate growth trends.
No financial data available for the latest quarter.
Analysts are generally positive on IFRX, with upgrades to Strong Buy and price targets raised to $8-$9. The focus is on the izicopan program, which shows potential in clinical development and broader complement-related opportunities.
